Canadian Concensus Conference on the management of gastroesophageal reflux disease in adults - Update 2004

Canadian Journal of Gastroenterology

Volumn 19, Issue 1, 2005, Pages 15-35

  Armstrong, David ^a   Marshall, John K ^a   Chiba, Naoki ^a,b   Enns, Robert ^c   Fallone, Carlo A ^d   Fass, Ronnie ^e   Hollingworth, Roger ^f   Hunt, Richard H ^a   Kahrilas, Peter J ^g   Mayrand, Serge ^d   Moayyedi, Paul ^a,h   Paterson, William G ⁱ   Sadowski, Dan ^j   Veldhuyzen van Zanten, Sander J O ^k  

^a MCMASTER UNIVERSITY   (Canada)

^b Surrey GI Research   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e UNIVERSITY OF ARIZONA   (United States)

^f CREDIT VALLEY HOSPITAL   (Canada)

^g NORTHWESTERN UNIVERSITY   (United States)

^h UNIVERSITY OF BIRMINGHAM   (United Kingdom)

ⁱ QUEEN S UNIVERSITY   (Canada)

^j ROYAL ALEXANDRA HOSPITAL   (Canada)

^k DALHOUSIE UNIVERSITY   (Canada)

more..

Author keywords

Barrett's epithelium; Endoscopy negative reflux disease; Erosive esophagitis; Gastroesophageal refulx disease (GERD); Proton pump inhibitor (PPI)

Indexed keywords

ALGINIC ACID; ANTACID AGENT; ANTIINFECTIVE AGENT; CISAPRIDE; CYANOCOBALAMIN; DOMPERIDONE; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

ABDOMINAL PAIN; ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; CANADA; CARCINOID; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DYSPEPSIA; ENDOSCOPIC SURGERY; ERADICATION THERAPY; ERUCTATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS PH; ESOPHAGUS RESECTION; EVIDENCE BASED MEDICINE; FLATULENCE; GASTROESOPHAGEAL REFLUX; HEADACHE; HEARTBURN; HELICOBACTER INFECTION; HUMAN; HYPERGASTRINEMIA; LIFESTYLE; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; NAUSEA; PH MEASUREMENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REFLUX ESOPHAGITIS; REVIEW; RISK FACTOR; STOMACH CANCER; SURGICAL TECHNIQUE; TREATMENT PLANNING; ADULT; CONFERENCE PAPER; DELPHI STUDY; HELICOBACTER PYLORI; HOSPITALIZATION; PRACTICE GUIDELINE;

ADULT; BARRETT ESOPHAGUS; DELPHI TECHNIQUE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 20044366374     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2005/836030     Document Type: Review

References (308)

1. Tougas G, Chen Y, Hwang P, Liu M, Eggleston A. Prevalence and impact of upper gastrointestinal symptoms in the Canadian population: Findings from the DIGEST study. Domestic/International Gastroenterology Surveillance Study. Am J Gastroenterol 1999;94:2845-54.
2. Revicki DA, Sorensen S, Maton PN, Orlando RC. Health-related quality of life outcomes of omeprazole versus ranitidine in poorly 0responsive symptomatic gastroesophageal reflux disease. Dig Dis 1998;16:284-91.
3. Revicki DA, Crawley JA, Zodet MW, Levine DS, Joelsson BO. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999;13:1621-30.
4. Mathias S, Colwell H, Miller D, et al. Health-related quality-of-life and quality-days incrementally gained in symptomatic nonerosive GERD patients treated with lansoprazole or ranitidine. Dig Dis Sci 2001;46:2416-23.
5. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965-73.
6. Revicki D, Wood M, Maton P, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998;104:252-8.
7. Beck IT, Champion MC, Lemire S, et al. The second Canadian consensus conference on the management of patients with gastroesophageal reflux disease. Can J Gastroenterol 1997;11(Suppl B):7B-20B.
8. Veldhuyzen van Zanten S, Flook N, Chiba N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ 2000;162:S3-23.
9. Dent J, Brun J, Fendrick A, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999;44(Suppl 2):S1-16.
10. Armstrong D. Endoscopic evaluation of gastro-esophageal reflux disease. Yale J Biol Med 1999;72:93-100.
11. Armstrong D, Bennett J, Blum A, et al. The endoscopic assessment of esophagitis: A progress report on observer agreement. Gastroenterology 1996;111:85-92.
12. Lundell L, Dent J, Bennett J, et al. Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172-80.
13. Kahrilas F, Quigley E. Clinical esophageal pH recording: A technical review for practice guideline development. Gastroenterology 1996;110:1982-96.
14. Rudolph C, Mazur L, Liptak G, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: Recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001;32(Suppl 2):S1-31.
15. Hayward RS, Wilson MC, Tunis SR, et al. More informative abstracts of articles describing clinical practice guidelines. Ann Intern Med 1993;118:731-7.
16. Lomas J. Words without action? The production, dissemination, and impact of consensus recommendations. Annu Rev Public Health 1991;12:41-65.
17. Field MJ, Lohr KN, eds. Clinical Practice Guidelines. Directions For a New Program. Washington, DC: National Academy Press, 1990.
18. Field MJ, Lohr KN, eds. Clinical Practice Guidelines: From Development to Use. Washington, DC: National Academy Press, 1992.
19. Cluzeau FA, Littlejohns P, Grimshaw JM, Feder G, Moran SE. Development and application of a generic methodology to assess the quality of clinical guidelines. Int J Qual Health Care 1999;11:21-8.
20. Eccles M, Clapp Z, Grimshaw J, et al. North of England evidence based guidelines development project: Methods of guideline development. BMJ 1996;312:760-2.
21. Talley N, Venables T, Green J, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: A placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002;14:857-63.
22. Cook DJ, Greengold NL, Ellrodt AG, Weingarten SR. The relation between systematic reviews and practice guidelines. Ann Intern Med 1997;127:210-6.
23. Dalkey N. An experimental study of group opinion: The Delphi Method. Futures 1969:408-26.
24. Canadian Task Force on the Periodic Health Examination. The periodic health examination: 1. Introduction. CMAJ 1986;134:721-3.
25. Giacomini M, Cook D, Streiner D, Anand S. Using practice guidelines to allocate medical technologies. An ethics framework. Int J Technol Assess Health Care 2000;16:987-1002.
26. Spechler S. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992;51(Suppl 1):24-9.
27. Wienbeck M, Barnett J. Epidemiology of reflux disease and reflux esophagitis. Scand J Gastroenterol Suppl 1989;156:7-13.
28. Akdamar K, Ertan A, Agrawal N, McMahon F, Ryan J. Upper gastrointestinal endoscopy in normal asymptomatic volunteers. Gastrointest Endosc 1986;32:78-80.
29. Shaheen N, Provenzale D. The epidemiology of gastroesophageal reflux disease. Am J Med Sci 2003;326:264-73.
30. Galmiche J, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: A double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997;11:765-73.
31. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998;10:119-24.
32. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: Efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974-9.
33. Thomson A, Barkun A, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: The Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003;17:1481-91.
34. Frank L, Kleinman L, Ganoczy D, et al. Upper gastrointestinal symptoms in North America: Prevalence and relationship to healthcare utilization and quality of life. Dig Dis Sci 2000;45:809-18.
35. Henke C, Levin T Henning J, Potter L. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization. Am J Gastroenterol 2000;95:788-92.
36. Dean B, Crawley J, Schmitt C, Wong J, Ofman J. The burden of illness of gastro-oesophageal reflux disease: Impact on work productivity. Aliment Pharmacol Ther 2003;17:1309-17.
37. Vakil N, Shaker R, Johnson D, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: A 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001;15:927-35.
38. Johnson D, Benjamin S, Vakil N, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: A randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001;96:27-34.
39. van Pinxteren B, Numans M, Lau J, et al. Short-term treatment of gastroesophageal reflux disease. J Gen Intern Med 2003;18:755-63.
40. Fass R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003;98:S2-7.
41. Garcia-Compean D, Gonzalez M, Galindo G, et al. Prevalence of gastroesophageal reflux disease in patients with extraesophageal symptoms referred from otolaryngology, allergy, and cardiology practices: A prospective study. Dig Dis 2000;18:178-82.
42. Hewson E, Sinclair J, Dalton C, Richter J. Twenty-four-hour esophageal pH monitoring: The most useful test for evaluating noncardiac chest pain. Am J Med 1991;90:576-83.
43. Lam H, Dekker W, Kan G, Breedijk M, Smout A. Acute noncardiac chest pain in a coronary care unit. Evaluation by 24-hour pressure and pH recording of the esophagus. Gastroenterology 1992;102:453-60.
44. Castell D, Kahrilas P, Richter J, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575-83.
45. Kahrilas P, Falk G, Johnson D, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000;14:1249-58.
46. Lauritsen K, Deviere J, Bigard M, et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment Pharmacol Ther 2003;17:333-41.
47. Richter J, Kahrilas P, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial. Am J Gastroenterol 2001;96:656-65.
48. DeVault K, Castell D, The Practice Parameters Committee of the American Gastroenterological Association. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999;94:1434-42.
49. Moayyedi P, Duffy J, Delaney B. New approaches to enhance the accuracy of the diagnosis of reflux disease. Gut 2004;53(Suppl 4):iv55-7.
50. Clouse R, Richter J, Heading R, Janssens J, Wilson J. Functional esophageal disorders. Gut 1999;45(Suppl 2):II31-6.
51. Fass R, Tougas G. Functional heartburn: The stimulus, the pain, and the brain. Gut 2002;51:885-92.
52. Moayyedi P, Forman D, Braunholtz; D, et al. The proportion of upper gastrointestinal symptoms in the community associated with Helicobacter pylori, lifestyle factors, and nonsteroidal anti-inflammatory drugs. Leeds HELP Study Group. Am J Gastroenterol 2000;95:1448-55.
53. Klauser A, Schindlbeck N, Muller-Lissner S. Symptoms in gastro-oesophageal reflux disease. Lancet 1990;335:205-8.
54. Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998;33:1023-9.
55. Fass R, Ofman J, Gralnek I, et al. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 1999;159:2161-8.
56. Schenk B, Kuipers E, Klinkenberg-Knol E, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997;92:1997-2000.
57. Fass R, Ofman J, Sampliner R, et al. The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment Pharmacol Ther 2000;14:389-96.
58. Armstrong D, Veldhuyzen van Zanten S, Barkun A, et al. Symptom improvement at one week to predict outcome at four weeks with esomeprazole (E) in uninvestigated dyspepsia (UD) patients: The confirmatory acid suppression test (CAST) study. Can J Gastroenterol 2004;18(Supp A):130A. (Abst)
59. Fass R, Fennerty M, Ofman J, et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 1998;115:42-9.
60. Bautista J, Fullerton H, Briseno M, Cui H, Fass R. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain - a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther 2004;19:1123-30.
61. Ofman J, Gralnek I, Udani J, Fennerty M, Fass R. The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. Am J Med 1999;107:219-27.
62. Spechler S. American Gastroenterological Association medical position statement on treatment of patients with dysphagia caused by benign disorders of the distal esophagus. Gastroenterology 1999;117:229-33.
63. Dakkak M, Bennett J. A new dysphagia score with objective validation. J Clin Gastroenterol 1992;14:99-100.
64. Richter J. Severe reflux esophagitis. Gastrointest Endosc Clin N Am 1994;4:677-98.
65. Armstrong D. Motion - All patients with GERD should be offered once in a lifetime endoscopy: Arguments for the motion. Can J Gastroenterol 2002;16:549-51.
66. Thjodleifsson B, Beker JA, Dekkers C, et al. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: A double-blind, multicenter, European trial. The European Rabeprazole Study Group. Dig Dis Sci 2000;45:845-53.
67. Nayar D, Vaezi M. Classifications of esophagitis: Who needs them? Gastrointest Endosc 2004;60:253-7.
68. Richter J. Diagnostic tests for gastroesophageal reflux disease. Am J Med Sci 2003;326:300-8.
69. Stolte M, Vieth M, Schmitz JM, Alexandridis T, Seifert E. Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus. Scand J Gastroenterol 2000;35:1125-30.
70. Armstrong D, Vieth M, Fiocca R, et al. Are endoscopy negative GERD and reflux esophagitis different diseases? Baseline histology in GERD patients off-therapy - the CHEER Study. Gastroenterology 2003;124:A416. (Abst)
71. Ismail-Beigi F, Horton P, Pope C. Histological consequences of gastroesophageal reflux in man. Gastroenterology 1970;58:163-74.
72. Tobey N, Carson J, Alkiek R, Orlando R. Dilated intercellular spaces: A morphological feature of acid reflux - damaged human esophageal epithelium. Gastroenterology 1996;111:1200-5.
73. Armstrong D, Vieth M, Deprez P, et al. Esomeprazole therapy and esophageal histology in endoscopy negative reflux disease (ENRD) - the CHEER Study. Gastroenterology 2003;124:A416. (Abst)
74. Solcia E, Villani L, Luinetti O, et al. Altered intercellular glycoconjugates and dilated intercellular spaces of esophageal epithelium in reflux disease. Virchows Arch 2000;436:207-16.
75. Martinez S, Malagon I, Garewal H, Cui H, Fass R. Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther 2003;17:537-45.
76. Johnston B, Troshinsky M, Castell J, Castell D. Comparison of barium radiology with esophageal pH monitoring in the diagnosis of gastroesophageal reflux disease. Am J Gastroenterol 1996;91:1181-5.
77. Poynard T, Vernisse B, Agostini H. Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux. Aliment Pharmacol Ther 1998;12:159-65.
78. Kitchin L, Castell D. Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med 1991;151:448-54.
79. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis. Gastroenterology 1997;112:1798-810.
80. Hunt R. Importance of pH control in the management of GERD. Arch Intern Med 1999;159:649-57.
81. Johansson K, Ask P, Boeryd B, Fransson S, Tibbling L. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol 1986;21:837-47.
82. Pujol A, Grande L, Ros E, Pera C. Utility of inpatient 24-hour intraesophageal pH monitoring in diagnosis of gastroesophageal reflux. Dig Dis Sci 1988;33:1134-40.
83. Masclee A, de Best A, de Graaf R, Cluysenaer O, Jansen J. Ambulatory 24-hour pH-metry in the diagnosis of gastroesophageal reflux disease. Determination of criteria and relation to endoscopy. Scand J Gastroenterol 1990;25:225-30.
84. Kasapidis P, Xynos E, Mantides A, et al. Differences in manometry and 24-H ambulatory pH-metry between patients with and without endoscopic or histological esophagitis in gastroesophageal reflux disease. Am J Gastroenterol 1993;88:1893-9.
85. Saraswat V, Dhiman R, Mishra A, Naik S. Correlation of 24-hr esophageal pH patterns with clinical features and endoscopy in gastroesophageal reflux disease. Dig Dis Sci 1994;39:199-205.
86. Hunt R. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9 Suppl 1:3-7.
87. Orlando R. Why is the high grade inhibition of gastric acid secretion afforded by proton pump inhibitors often required for healing of reflux esophagitis? An epithelial perspective. Am J Gastroenterol 1996;91:1692-6.
88. Bell N, Hunt R. Progress with proton pump inhibition. Yale J Biol Med 1992;65:649-57.
89. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: Evidence from randomized clinical trials. Clin Ther 2001;23:998-1017.
90. Armstrong D. 'Start high' - a better acid suppression strategy for heartburn-dominant uninvestigated dyspepsia (UD) in primary care practice (PCP) - the CADET-HR study. Can J Gastroenterol 2002;16(Suppl A):144A. (Abst)
91. Festen H, Schenk E, Tan G, Snel P, Nelis F. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: Short- and long-term treatment. The Dutch Reflux Study Group. Am J Gastroenterol 1999;94:931-6.
92. Jansen J, Van OJ. Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group. Aliment Pharmacol Ther 1999;13:1611-20.
93. Kahrilas P, Fennerty M, Joelsson B. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am J Gastroenterol 1999;94:92-7.
94. Ehrlich A, Lucker P, Wiedemann A, et al. Comparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administration. Methods Find Exp Clin Pharmacol 1999;21:47-51.
95. Galmiche J, Zerbib F, Ducrotte P, et al. Decreasing oesophageal acid exposure in patients with GERD: A comparison of rabeprazole and omeprazole. Aliment Pharmacol Ther 2001;15:1343-50.
96. Dammann H, Burkhardt F. Pantoprazole versus omeprazole: Influence on meal-stimulated gastric acid secretion. Eur J Gastroenterol Hepatol 1999;11:1277-82.
97. Katz P, Hatlebakk J, Castell D. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther 2000;14:709-14.
98. Katz P, Xue S, Castell D. Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg. Aliment Pharmacol Ther 2001;15:647-52.
99. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum A. Acid inhibition on the first day of dosing: Comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003;17:1507-14.
100. Frazzoni M, De ME, Grisendi A, Savarino V. Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: Lansoprazole vs. pantoprazole. Aliment Pharmacol Ther 2003;17:235-41.
101. Huang J, Goldwater D, Thomson A, et al. Acid suppression in healthy subjects following lansoprazole or pantoprazole. Aliment Pharmacol Ther 2002;16:425-33.
102. Wilder-Smith C, Rohss K, Nilsson-Pieschl C, Junghard O, Nyman L. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. Digestion 2003;68:184-8.
103. Miner P, Katz P, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: A five-way crossover study. Am J Gastroenterol 2003;98:2616-20.
104. Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000;14:861-7.
105. Rohss K, Hasselgren G, Hedenstrom H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 2002;47:954-8.
106. Wilder-Smith C, Bondarov P, Hallerbäck B, et al. Esomeprazole 40 mg intravenous provides faster and more effective acid control than pantoprazole 40 mg intravenous after first dose and 5 days. Gut 2003;52(Suppl VI):A129. (Abst)
107. Simon B, Muller P, Pascu O, et al. Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: A crossover study in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2003;15:791-9.
108. Wilder-Smith C, Lind T, Lundin C, et al. Comparison of esomeprazole 20, 40, 80 mg versus lansoprazole 15, 30, 60 mg on intragastric Ph in healthy subjects. Gut 2003;52(Suppl VI):A124. (Abst)
109. Schindlbeck N, Klauser A, Voderholzer W, Muller-Lissner S. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med 1995;155:1808-12.
110. Klok R, Postma M, van Hout B, Brouwers J. Meta-analysis: Comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther 2003;17:1237-45.
111. Labenz J, Keeling P, Eklund S, Nauclet E, on behalf of the Expo Study Group. A comparison of esomeprazole 40 mg once-daily and pantoprazole 40 mg once-daily for the healing of erosive esophagitis. Can J Gastroenterol 2004;18(Suppl A):118A. (Abst)
112. Gillessen A, Beil W, Modlin I, Gatz G, Hole U. 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J Clin Gastroenterol 2004;38:332-40.
113. Tack J, Fass R. Review article: Approaches to endoscopic-negative reflux disease: Part of the GERD spectrum or a unique acid-related disorder? Aliment Pharmacol Ther 2004;19(Suppl 1):28-34.
114. Miner P, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: A randomized placebo-controlled trial. Am J Gastroenterol 2002;97:1332-9.
115. Armstrong D, Talley N, Lauritsen K, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: The effect of treatment with esomeprazole, or omeprazole. Aliment Pharmacol Ther 2004;20:413-21.
116. Howden C, Henning J, Huang B, Lukasik N, Freston J. Management of heartburn in a large, randomized, community-based study: Comparison of four therapeutic strategies. Am J Gastroenterol 2001;96:1704-10.
117. van Rensburg C, Honiball P, Grundling H, et al. Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis. Aliment Pharmacol Ther 1996;10:397-401.
118. Fass R, Murthy U, Hayden C, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoptazole therapy - a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000;14:1595-603.
119. Hetzel D, Dent J, Reed W, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95:903-12.
120. Richter J, Peura D, Benjamin S, Joelsson B, Whipple J. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med 2000;160:1810-6.
121. Richter J, Bochenek W. Oral pantoprazole for erosive esophagitis: A placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol 2000;95:3071-80.
122. Castell D, Richter J, Robinson M, Sontag S, Haber M. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol 1996;91:1749-57.
123. Frazzoni M, De ME, Grisendi A, Savarino V. Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: A pH-metric comparison. Aliment Pharmacol Ther 2002; 16:35-9.
124. Hatlebakk J, Katz P, Kuo B, Castell D. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998;12:1235-40.
125. Hatlebakk J, Katz P, Camacho-Lobato L, Castell D. Proton pump inhibitors: Better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000;14:1267-72.
126. Kuo B, Castell D. Optimal dosing of omeprazole 40 mg daily: Effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996;91:1532-8.
127. Lundell L, Miettinen P, Myrvold H, et al. Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: Results of a prospective, randomized clinical trial. The Nordic GORD Study Group. Eur J Gastroenterol Hepatol 2000;12:879-87.
128. Armstrong D. The clinical usefulness of prokinetic agents in gastro-oesophageal reflux disease. In: Lundell L, ed. Guidelines for Management of Symptomatic Gastro-oesophageal Reflux Disease. London: Science Press, 1998:45-54.
129. Augood C, MacLennan S, Gilbert R, Logan S. Cisapride treatment for gastro-oesophageal reflux in children (Cochrane Review). The Cochrane Library. Chichester, United Kingdom: John Wiley & Sons Ltd, 2004.
130. 2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. (Cochrane Review). The Cochrane Library. Chichester, United Kingdom: John Wiley & Sons Ltd, 2004.
131. Bines J, Quinlan J, Treves S, Kleinman R, Winter H. Efficacy of domperidone in infants and children with gastroesophageal reflux. J Pediatr Gastroenterol Nutr 1992;14:400-5.
132. Maddern G, Kiroff G, Leppard P, Jamieson G. Domperidone, metoclopramide, and placebo. All give symptomatic improvement in gastroesophageal reflux. J Clin Gastroenterol 1986;8:135-40.
133. Carroccio A, Iacono G, Montalto G, et al. Domperidone plus magnesium hydroxide and aluminum hydroxide: A valid therapy in children with gastroesophageal reflux. A double-blind randomized study versus placebo. Scand J Gastroenterol 1994;29:300-4.
134. McCallum R, Fink S, Winnan G, Avella J, Callachan C. Metoclopramide in gastroesophageal reflux disease: Rationale for its use and results of a double-blind trial. Am J Gastroenterol 1984;79:165-72.
135. Guslandi M, Testoni P, Passaretti S, et al. Ranitidine vs metoclopramide in the medical treatment of reflux esophagitis. Hepatogastroenterology 1983;30:96-8.
136. Orr W, Finn A, Wilson T, Russell J. Esophageal acid contact time and heartburn in acute treatment with ranitidine and metoclopramide. Am J Gastroenterol 1990;85:697-700.
137. Kimmig J. Treatment and prevention of relapse of mild oesophagitis with omeprazole and cisapride: Comparison of two strategies. Aliment Pharmacol Ther 1995;9:281-6.
138. van Rensburg C, Bardhan K. No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2001;13:909-14.
139. Masci E, Testoni P, Passaretti S, Guslandi M, Tittobello A. Comparison of ranitidine, domperidone maleate and ranitidine + domperidone maleate in the short-term treatment of reflux oesophagitis. Drugs Exp Clin Res 1985;11:687-92.
140. Richter J, Sabesin S, Kogut D, et al. Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease. Am J Gastroenterol 1996;91:1766-72.
141. Bloom BS, Hillman AL, LaMont B, Liss C, Schwartz JS, Stever GJ. Omeprazole or ranitidine plus metoclopramide for patients with severe erosive oesophagitis. A cost-effectiveness analysis. Pharmacoeconomics 1995;8:343-9.
142. Robinson M, Decktor D, Maton P, et al. Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis. Aliment Pharmacol Ther 1993;7:67-73.
143. Arabehety J, Leitao O, Fassler S, Olarte M, Serrano C. Cisapride and metoclopramide in the treatment of gastroesophageal reflux disease. Clin Ther 1988;10:421-8.
144. Lieberman D, Keeffe E. Treatment of severe reflux esophagitis with cimetidine and metoclopramide. Ann Intern Med 1986;104:21-6.
145. Shiau J, Shukla V, Dubé C. The efficacy of proton pump inhibitors in adults with functional dyspepsia. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2002; Technology report no. 22.
146. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999;13:907-14.
147. Wilhelmsen I, Hatlebakk JG, Olafsson S, Berstad A. On demand therapy of reflux oesophagitis - a prospective study of symptoms, patient satisfaction and quality of life. Aliment Pharmacol Ther 1999;13:1035-40.
148. Talley N, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001;15:347-54.
149. Dent J, Talley N. Overview: Initial and long-term management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003;17(Suppl 1):53-7.
150. Sontag S, Robinson M, Roufail W, et al. Daily omeprazole surpasses intermittent dosing in preventing relapse of oesophagitis: A US multi-centre double-blind study. Aliment Pharmacol Ther 1997;11:373-80.
151. Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol 2003;98:S31-9.
152. Pohle T, Domschke W. Results of short-and long-term medical treatment of gastroesophageal reflux disease (GERD). Langenbecks Arch Surg 2000;385:317-23.
153. Freston J, Triadafilopoulos G. Approaches to the long-term management of adults with GERD-proton pump inhibitor therapy, laparoscopic fundoplication or endoscopic therapy? Aliment Pharmacol Ther 2004;19(Suppl 1):35-42.
154. Richter J. Long-term management of gastroesophageal reflux disease and its complications. Am J Gastroenterol 1997;92:30S-4S; discussion 4S-5S.
155. Barbezat G, Schlup M, Lubcke R. Omeprazole therapy decreases the need for dilatation of peptic oesophageal strictures. Aliment Pharmacol Ther 1999;13:1041-5.
156. Stal J, Gregor J, Preiksaitis H, Reynolds R. A cost-utility analysis comparing omeprazole with ranitidine in the maintenance therapy of peptic esophageal stricture. Can J Gastroenterol 1998;12:43-9.
157. Smith P, Kerr G, Cockel R, et al. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Restore Investigator Group. Gastroenterology 1994;107:1312-8.
158. 2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994;106:907-15.
159. Swarbrick E, Gough A, Foster C, et al. Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine. Eur J Gastroenterol Hepatol 1996;8:431-8.
160. Carlsson R, Galmiche J, Dent J, Lundell L, Frison L. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: A meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997;11:473-82.
161. Laursen L, Havelund T, Bondesen S, et al. Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study. Scand J Gastroenterol 1995;30:839-46.
162. Plein K, Hotz J, Wurzer H, et al. Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2000;12:425-32.
163. Escourrou J, Deprez P, Saggioro A, et al. Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis. Aliment Pharmacol Ther 1999;13:1481-91.
164. Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: A systematic overview. Can J Gastroenterol 1997;11(Suppl B):66B-73B.
165. Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;124:859-67.
166. 2-RA therapy. The Lansoprazole Maintenance Study Group. Am J Gastroenterol 1996;91:1758-65.
167. Baldi F, Morselli-Labate A, Cappiello R, Ghersi S. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis. Am J Gastroenterol 2002;97:1357-64.
168. Caos A, Moskovitz M, Dayal Y, et al. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group. Am J Gastroenterol 2000;95:3081-8.
169. Metz D, Bochenek W. Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. Aliment Pharmacol Ther 2003;17:155-64.
170. Hatlebakk J, Berstad A. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Aliment Pharmacol Ther 1997;11:365-72.
171. Lundell L, Miettinen P, Myrvold HE, et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 2001;192:172-9; discussion 9-81.
172. Klinkenberg Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118:661-9.
173. Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion 2001;64:205-13.
174. Maton P, Vakil N, Levine J, et al. Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis. Drug Saf 2001;24:625-35.
175. Freston J, Jackson R, Huang B, Ballard E. Lansoprazole for maintenance of remission of erosive oesophagitis. Drugs 2002;62:1173-84.
176. Freston J, Rose P, Heller C, Haber M, Jennings D. Safety profile of Lansoprazole: The US clinical trial experience. Drug Saf 1999;20:195-205.
177. Bardhan K, Cherian P, Bishop A, et al. Pantoprazole therapy in the long-term management of severe acid peptic disease: Clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies. Am J Gastroenterol 2001;96:1767-76.
178. Van Rensburg CJ, Honiball PJ, Van Zyl JH, et al. Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up. Aliment Pharmacol Ther 1999;13:1023-8.
179. Thjodleifsson B, Rindi G, Fiocca R, et al. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment Pharmacol Ther 2003;17:343-51.
180. Laine L, Ahnen D, McClain C, Solcia E, Walsh J. Review article: Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000;14:651-68.
181. Cheer S, Prakash A, Faulds D, Lamb H. Pantoprazole: An update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003;63:101-33.
182. Flockhart D, Desta Z, Mahal S. Selection of drugs to treat gastro-oesophageal reflux disease: The role of drug interactions. Clin Pharmacokinet 2000;39:295-309.
183. Martin R, Dunn N, Freemantle S, Shakir S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: Cohort studies. Br J Clin Pharmacol 2000;50:366-72.
184. Avner D. Clinical experience with pantoprazole in gastroesophageal reflux disease. Clin Ther 2000;22:1169-85; discussion 49,50.
185. Bardhan K, Van Rensburg C. Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis. Aliment Pharmacol Ther 2001;15:1585-91.
186. Richter J, Campbell D, Kahrilas F, Huang B, Fludas C. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000;160:1803-9.
187. Tytgat G, Blum A, Verlinden M. Prognostic factors for relapse and maintenance treatment with cisapride in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9:271-80.
188. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333:1106-10.
189. Kahrilas P, Quigley E, Castell D, Spechler S. The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000;14:1503-9.
190. Cange L, Johnsson E, Rydholm H, et al. Baclofen-mediated gastro-oesophageal acid reflux control in patients with established reflux disease. Aliment Pharmacol Ther 2002;16:869-73.
191. Koek G, Sifrim D, Lerut T, Janssens J, Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003;52:1397-402.
192. Ciccaglione A, Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 2003;52:464-70.
193. Peghini P, Katz P, Bracy N, Castell D. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998;93:763-7.
194. Orr W, Harnish M. The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity. Aliment Pharmacol Ther 2003;17:1553-8.
195. Ours T, Fackler W, Richter J, Vaezi M. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003;98:545-50.
196. Peghini P, Katz P, Castell D. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998;115:1335-9.
197. 2RA therapy on nocturnal gastric acid breakthrough. Gastroentology 2002;122:625-32.
198. 2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001;15:1351-6.
199. Khoury R, Katz P, Hammod R, Castell D. Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH. Aliment Pharmacol Ther 1999;13:675-8.
200. Myrvold H, Lundell L, Miettinen P, et al. The cost of long term therapy for gastro-oesophageal reflux disease: A randomised trial comparing omeprazole and open antireflux surgery. Gut 2001;49:488-94.
201. Spechler S. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. N Engl J Med 1992;326:786-92.
202. Spechler S, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: Follow-up of a randomized controlled trial. JAMA 2001;285:2331-8.
203. Campos G, Peters J, De Meester T, et al. Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg 1999;3:292-300.
204. Power C, Maguire D, McAnena O. Factors contributing to failure of laparoscopic Nissen fundoplication and the predictive value of preoperative assessment. Am J Surg 2004;187:457-63.
205. Finlayson S, Laycock W, Birkmeyer J. National trends in utilization and outcomes of antireflux surgery. Surg Endosc 2003;17:864-7.
206. Rantanen T, Salo J, Sipponen J. Fatal and life-threatening complications in antireflux surgery: analysis of 5,502 operations. Br J Surg 1999;86:1573-7.
207. Leggett PL, Bissell CD, Churchman Winn R, Ahn C. A comparison of laparoscopic Nissen fundoplication and Rossetti's modification in 239 patients. Surg Endosc 2000;14:473-7.
208. Heikkinen TJ, Haukipuro K, Bringman S, et al. Comparison of laparoscopic and open Nissen fundoplication 2 years after operation. A prospective randomized trial. Surg Endosc 2000;14:1019-23.
209. Carlson M, Frantzides C. Complications and results of primary minimally invasive antireflux procedures: A review of 10,735 reported cases. J Am Coll Surg 2001;193:428-39.
210. Flum D, Koepsell T, Heagerty P, Pellegrini C. The nationwide frequency of major adverse outcomes in antireflux surgery and the role of surgeon experience, 1992-1997. J Am Coll Surg 2002;195:611-8.
211. Catarci M, Gentileschi P, Papi C, et al. Evidence-based appraisal of antireflux fundoplication. Ann Surg 2004;239:325-37.
212. Triadafilopoulos G, Di Baise J, Nostrant T, et al. The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the U.S. open label trial. Gastrointest Endosc 2002;55:149-56.
213. Filipi C, Lehman G, Rothstein R, et al. Transoral, flexible endoscopic suturing for treatment of GERD: A multicenter trial. Gastrointest Endosc 2001;53:416-22.
214. Feretis C, Benakis P, Dimopoulos C, et al. Endoscopic implantation of Plexiglas (PMMA) microspheres for the treatment of GERD. Gastrointest Endosc 2001;53:423-6.
215. Johnson D, Ganz R, Aisenberg J, et al. Endoscopic implantation of enteryx for treatment of GERD: 12-month results of a prospective, multicenter trial. Am J Gastroenterol 2003;98:1921-30.
216. Corley D, Katz F, Wo J, et al. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: A randomized, sham-controlled trial. Gastroenterology 2003;125:668-76.
217. Di Baise J, Brand R, Quigley E. Endoluminal delivery of radiofrequency energy to the gastroesophageal junction in uncomplicated GERD: Efficacy and potential mechanism of action. Am J Gastroenterol 2002;97:833-42.
218. Triadafilopoulos G, Dibaise J, Nostrant T, et al. Radiofrequency energy delivery to the gastroesophageal junction for the treatment of GERD. Gastrointest Endosc 2001;53:407-15.
219. Wolfsen H, Richards W. The Stretta procedure for the treatment of GERD: A registry of 558 patients. J Laparoendosc Adv Surg Tech A 2002;12:395-402.
220. Houston H, Khaitan L, Holzman M, Richards W. First year experience of patients undergoing the Stretta procedure. Surg Endosc 2003;17:401-4.
221. Mahmood Z, McMahon B, Arfin Q, et al. Endocinch therapy for gastro-oesophageal reflux disease: A one year prospective follow up. Gut 2003;52:34-9.
222. Johnson D, Ganz R, Aisenberg J, et al. Endoscopic, deep mural implantation of Enteryx for the treatment of GERD: 6-month follow-up of a multicenter trial. Am J Gastroenterol 2003;98:250-8.
223. Verdu E, Armstrong D, Idstrom J, et al. Effect of curing Helicobacter Pylori infection on intragastric pH during treatment with omeprazole. Gut 1995;37:743-8.
224. Kuipers E, Klinkenberg-Knol E, Meuwissen S. Helicobacter pylori, proton pump inhibitors and gastroesophageal reflux disease. Yale J Biol Med 1999;72:211-8.
225. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pyloyi infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999;117:11-6.
226. Armstrong D, Paré P, Pericak D, Pyzyk M. Symptom relief in gastroesophageal reflux disease: A randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol 2001;96:2849-57.
227. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
228. Kuipers E, Nelis G, Klinkenberg-Knol E, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: Results of a randomised controlled trial. Gut 2004;53:12-20.
229. Chiba N, Veldhuyzen van Zanten S, Sinclair P, et al. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: The Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002;324:1012-6.
230. Moayyedi P, Feltbower R, Brown J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: A randomised controlled trial. Leeds HELP Study Group. Lancet 2000;355:1665-9.
231. Wildner-Christensen M, Moller Hansen J, Schaffalitzky De Muckadell O. Rates of dyspepsia one year after Helicobacter pylori screening and eradication in a Danish population. Gastroenterology 2003;125:372-9.
232. Moayyedi P, Bardhan C, Young L, et al. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001;121:1120-6.
233. Fallone C, Barkun A, Friedman G, et al. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol 2000;95:914-20.
234. Labenz J. Does Helicobacter pylori affect the management of gastroesophageal reflux disease? Am J Gastroenterol 1999;94:867-9.
235. Labenz J, Malfertheiner P. Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor? Gut 1997;41:277-80.
236. Fallone CA, Barkun AN, Gottke MU, et al. Association of Helicobacter pylori genotype with gastroesophageal reflux disease and other upper gastrointestinal diseases. Am J Gastroenterol 2000;95:659-69.
237. Holtmann G. Reflux disease: The disorder of the third millennium. Eur J Gastroenterol Hepatol 2001;13(Suppl 1):S5-11.
238. Sharma P. Helicobacter pylori: A debated factor in gastroesophageal reflux disease. Dig Dis 2001;19:127-33.
239. Porro G, Pace F Should we eradicate Helicobacter pylori in patients with recurrent gastro-oesophageal reflux disease? Eur J Gastroenterol Hepatol 2000;12(Suppl 1):S7-10.
240. Kuipers E, Uyterlinde A, Pena A, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: Implications for long-term safety. Am J Gastroenterol 1995;90:1401-6.
241. Lundell L, Miettinen F, Myrvold H, et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic GERD Study Group. Gastroenterology 1999;117:319-26.
242. Hunt R, Fallone C, Thomson A. Canadian Helicobacter pylori Consensus Conference update: infections in adults. Canadian Helicobacter Study Group. Can J Gastroenterol 1999;13:213 -7.
243. Sampliner R. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002;97:1888-95.
244. Cameron A, Zinsmeister A, Ballard D, Carney J. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990;99:918-22.
245. Conio M, Cameron A, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 2001;48:304-9.
246. Csendes A, Smok G, Burdiles P, et al. Prevalence of Barrett's esophagus by endoscopy and histologic studies: A prospective evaluation of 306 control subjects and 376 patients with symptoms of gastroesophageal reflux. Dis Esophagus 2000;13:5-11.
247. Fallone C, Bradette M, Chiba N. Barrett's esophagus. In: MacDonald J, ed. Evidence-Based Gastroenterology. London: BMA House, 2004. (In press)
248. Mueller J, Werner M, Siewert J. Malignant progression in Barrett's esophagus: Pathology and molecular biology. Recent Results Cancer Res 2000;155:29-41.
249. Reid B, Levine D, Longton G, Blount P, Rabinovitch P. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
250. Shaheen N, Crosby M, Bozymski E, Sandler R. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8.
251. Provenzale D, Schmitt C, Wong J. Barrett's esophagus: A new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999;94:2043-53.
252. Rana P, Johnston D. Incidence of adenocarcinoma and mortality in patients with Barrett's oesophagus diagnosed between 1976 and 1986: Implications for endoscopic surveillance. Dis Esophagus 2000;13:28-31.
253. O'Connor J, Falk G, Richter J. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999;94:2037-42.
254. Drewitz D, Sampliner R, Garewal H. The incidence of adenocarcinoma in Barrett's esophagus: A prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92:212-5.
255. Conio M, Blanchi S, Lapertosa G, et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003;98:1931-9.
256. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
257. Lieberman D, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol 1997;92:1293-7.
258. Velanovich V, Hollingsworth J, Suresh P, Ben-Menachem T. Relationship of gastroesophageal reflux disease with adenocarcinoma of the distal esophagus and cardia. Dig Surg 2002;19:349-53.
259. Green J, Amaro R, Barkin J. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. Dig Dis Sci 2000;45:2367-8.
260. Avidan B, Sonnenberg A, Schnell T, et al. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002;97:1930-6.
261. 2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 2000;11:231-8.
262. Peters F, Ganesh S, Kuipers E, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment: A randomised double blind study. Gut 1999;45:489-94.
263. Ortiz A, Martinez de Haro L, Parrilla P, et al. Conservative treatment versus antireflux surgery in Barrett's oesophagus: Long-term results of a prospective study. Br J Surg 1996;83:274-8.
264. Parrilla P, Martinez de Haro L, Ortiz A, et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 2003;237:291-8.
265. Csendes A, Burdiles P, Braghetto I, et al. Dysplasia and adenocarcinoma after classic antireflux surgery in patients with Barrett's esophagus: The need for long-term sujective and objective follow-up. Ann Surg 2002;235:178-85.
266. Corey K, Schmitz S, Shaheen N. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol 2003;98:2390-4.
267. Spechler S. Barrett's esophagus: An overrated cancer risk factor. Gastroenterology 2000;119:587-9.
268. MacNeil-Covin L, Casson A, Malatjalian D, Veldhuyzen van Zanten S. A survey of Canadian gastroenterologists about the management of Barrett's esophagus. Can J Gastroenterol 2003;17:313-7.
269. Shaheen N, Ransohoff D. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: Scientific review. JAMA 2002;287:1972-81.
270. Romagnuolo J, Meier M, Sadowski D. Medical or surgical therapy for erosive reflux esophagitis: Cost-utility analysis using a Markov model. Ann Surg 2002;236:191-202.
271. Marshall J, Armstrong D, O'Brien B. Test and treat strategies for Helicobacter pylori in uninvestigated dyspepsia: A Canadian economic analysis. Can J Gastroenterol 2000;14:379-88.
272. Spechler S, Barr H. Screening and surveillance of Barrett's oesophagus: What is a cost-effective framework? Aliment Pharmacol Ther 2004;19(Suppl 1):49-53.
273. Inadomi J, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett esophagus in high-risk groups: A cost-utility analysis. Ann Intern Med 2003;138:176-86.
274. Spechler SJ. Clinical practice. Barrett's esophagus. N Engl J Med 2002;346:836-42.
275. Schnell T, Sontag S, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607-19.
276. Buttar N, Wang K, Sebo T, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630-9.
277. Peters J, Clark G, Ireland A, et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994;108:813-21; discussion 21-2.
278. Corley D, Levin T, Habel L, Weiss N, Buffler P. Surveillance and survival in Barrett's adenocarcinomas: A population-based study. Gastroenterology 2002;122:633-40.
279. Streitz J, Andrews C, Ellis F. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 1993;105:383-7; discussion 7-8.
280. van Sandick J, van Lanschot J, Kuiken B, et al. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998;43:216-22.
281. Cancer Surveillance Online. Cancer incidence by province/territory. Cancer of the esophagus, both sexes combined, all ages. Health Canada, 2000 http://dsol-smed.hc-sc.gc.ca/dsol-smed/cgi-bin/cancerchart2?CAUSE1 =031&SEX1=3&YEAR1=00&DATA_TYPE= R&AGE1=0&CPROV1=View+Chart (Version current at December 15, 2004).
282. Bytzer P, Christensen P, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett's esophagus: A population-based study. Am J Gastroenterol 1999;94:86-91.
283. van der Burgh A, Dees J, Hop W, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996;39:5-8.
284. Overholt B, Haggitt R, Bronner M, et al. A multicenter, partially blinded randomized study of the efficacy of photodynamic therapy (PDT) using porfimer sodium (POR) for the ablation of high grade dysplasia (HGD) in Barrett's esophagus (BE): Results of a 6 month follow up. Gastroenterology 2001;120:A79.
285. Overholt B, Panjehpour M, Halberg D. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: Long-term results. Gastrointest Endosc 2003;58:183-8.
286. Ackroyd R, Brown N, Davis M, et al. Photodynamic therapy for dysplastic Barrett's oesophagus: A prospective, double blind, randomised, placebo controlled trial. Gut 2000;47:612-7.
287. Overholt B, Lightdale C, Wang K, et al. International, multicenter, partially blinded, randomized study of the efficacy of photodynamic therapy (PDT) using porfimer sodium (POR) for the ablation of high-grade dysplasia (HGD) in Barrett's esophagus (BE): Results of 24-month follow-up. Gastroenterology 2003;124:A20. (Abst)
288. Moreira L, Kamikawa Y, Naomoto Y, Haisa M, Orita K. Endoscopic mucosal resection for superficial carcinoma and high-grade dysplasia of the esophagus. Surg Laparosc Endosc 1995;5:171-5.
289. Ahmad N, Kochman M, Long W, Furth E, Ginsberg G. Efficacy, safety, and clinical outcomes of endoscopic mucosal resection: A study of 101 cases. Gastrointest Endosc 2002;55:390-6.
290. Nijhawan P, Wang K. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus. Gastrointest Endosc 2000;52:328-32.
291. Lundell L. Surgical therapies in Barrett's esophagus. Gastrointest Endosc Clin N Am 2003;13:433-47, vi.
292. DeMeester TR. Surgical treatment of dysplasia and adenocarcinoma. Gastroenterol Clin North Am 1997;26:669-84.
293. Csendes A. Surgical treatment of Barrett's esophagus: 1980-2003. World J Surg 2004;28:225-31.
294. O'Riordan JM, Byrne PJ, Ravi N, Keeling PW, Reynolds JV. Long-term clinical and pathologic response of Barrett's esophagus after antireflux surgery. Am J Surg 2004;188:27-33.
295. Ruol A, Zaninotto G, Costantini M, et al. Barrett's esophagus: Management of high-grade dysplasia and cancer. J Surg Res 2004;117:44-51.
296. Marcon N. Photodynamic therapy and cancer of the esophagus. Semin Oncol 1994;21:20-3.
297. van den Boogert J, van Hillegersberg R, Siersema P, de Bruin R, Tilanus H. Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: A review. Am J Gastroenterol 1999;94:1153-60.
298. Sandler R, Everhart J, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500-11.
299. IMS Health. Academic Reference Manual. Pointe-Claire, Quebec: IMS, 2002.
300. Kaplan-Machlis B, Spiegler G, Zodet M, Revicki D. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Arch Fam Med 2000;9:624-30.
301. Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 2000;95:395-407.
302. Harris RA, Kuppermann M, Richter JE. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: A cost-effectiveness analysis. Am J Gastroenterol 1997;92:2179-87.
303. Goeree R, O'Brien B, Hunt R, et al. Economic evaluation of long-term management strategies for erosive oesophagitis. Pharmacoeconomics 1999;16:679-97.
304. Ofman J, Yamashita B, Siddique R, Larson L, Willian M. Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis. Am J Manag Care 2000;6:905-16.
305. O'Brien B, Goeree R, Hunt R, et al. Cost-effectiveness of alternative therapies for the long-term management of gastroesophageal reflux disease. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1996
306. Goeree R, O'Brien B, Blackhouse G, et al. Cost-effectiveness and cost-utility of long-term management strategies for heartburn. Value Health 2002;5:312-28.
307. Wahlqvist P, Junghard O, Higgins A, Green J. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: Comparison of on-demand esomeprazole with conventional omeprazole strategies. Pharmacoeconomics 2002;20:267-77.
308. Wahlqvist P, Junghard O, Higgins A, Green J. Cost effectiveness of esomeprazole, compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK. Pharmacoeconomics 2002;20:279-87.